Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10508118 | 0.78 | TLR3 (0.48) | HIF1AEPAS1 | |
| SCHEMBL29400720 | 0.76 | HSP90AA1 (0.42) | COXFA4HSP90AA1 | |
| SCHEMBL546720 | 0.76 | HSP90AA1 (0.42) | COXFA4HSP90AA1 | |
| SCHEMBL546699 | 0.76 | HSP90AA1 (0.42) | COXFA4HSP90AA1 | |
| SCHEMBL10507493 | 0.75 | TLR3 (0.50) | HIF1AEPAS1 | |
| SCHEMBL11012720 | 0.74 | TLR3 (0.48) | HIF1AEPAS1COXFA4 | |
| SCHEMBL545855 | 0.72 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDTDP1HIF1A | |
| SCHEMBL6702779 | 0.71 | MEN1 (0.52) | ALDH1A1TDP1 | |
| SCHEMBL8078006 | 0.70 | GAA (0.67) | TDP1 | |
| SCHEMBL10510924 | 0.70 | TLR3 (0.53) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46228-E1 | Pigmentation-regulating compounds | LIPOTEC, S.A. (ES) | 2016-12-06 | — | — | US | disclosed |
| EP-2159223-B1 | 6 -ACYLOXY- 7-METH0XY- 2, 2 -DIMETHYLCHROMANE COMPOUNDS AND THEIR USE AS PIGMENTATION-REGULATORS | LIPOTEC SA (ES) | 2014-03-12 | — | — | EP | disclosed |
| US-8110207-B2 | Pigmentation-regulating compounds | LIPOTEC, S.A. (ES) | 2012-02-07 | — | — | US | disclosed |
| US-20100247587-A1 | PIGMENTATION-REGULATING COMPOUNDS | LIPOTEC, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2159223-A2 | 6 -ACYLOXY- 7-METH0XY- 2, 2 -DIMETHYLCHROMANE COMPOUNDS AND THEIR USE AS PIGMENTATION-REGULATORS | Lipotec, S.A. (ES) | 2010-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247587-A1 | PIGMENTATION-REGULATING COMPOUNDS | TYR, MC1R, MITF | ALDH1A1 728/4885CYP3A4 3232/4885HPGD 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.